News Releases Overview News & Events Stock Corporate Governance Financial Information Shareholder Services News Releases Events Presentations Year All2026202520242023 May 28, 2026 Veradermics to Present at Upcoming June Investor Conferences May 27, 2026 Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research May 14, 2026 Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium May 12, 2026 Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress April 29, 2026 Veradermics Announces Pricing of Upsized Public Offering and Private Placement April 27, 2026 Veradermics Announces Launch of Public Offering April 27, 2026 Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss April 26, 2026 Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss March 30, 2026 Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates March 18, 2026 Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
Year All2026202520242023 May 28, 2026 Veradermics to Present at Upcoming June Investor Conferences May 27, 2026 Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research May 14, 2026 Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium May 12, 2026 Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress April 29, 2026 Veradermics Announces Pricing of Upsized Public Offering and Private Placement April 27, 2026 Veradermics Announces Launch of Public Offering April 27, 2026 Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss April 26, 2026 Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss March 30, 2026 Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates March 18, 2026 Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
